<DOC>
	<DOCNO>NCT00003790</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure may improve ability detect residual disease . PURPOSE : Clinical trial detect presence residual disease child receive therapy acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Detection Residual Disease Children Receiving Therapy Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine frequency prognostic significance persistent abnormal cell aberrant phenotype detect multidimensional flow cytometry ( MDF ) bone marrow sample child achieve clinical remission receive treatment acute myeloid leukemia myelodysplastic syndrome . II . Compare frequency persistent abnormal cell obtain MDF polymerase chain reaction ( PCR ) , morphologic , cytogenetic analysis patient sample . III . Determine frequency prognostic significance persistent abnormal cell leukemia-specific molecular marker detect PCR sample patient . OUTLINE : Patients bone marrow sample collect course therapy CCG 2961 acute myeloid leukemia treatment protocol . These sample collect : 1 . At time diagnosis 2 . At end induction ( within week day 35 ) 3 . At end consolidation ( bone marrow transplant Capizzi 2 ) 4 . Before interleukin-2 ( IL-2 ) therapy , applicable 5 . At end therapy ( transplant evidence engraftment autologous bone marrow transplant patient ; course 2 intensification chemotherapy patient ; IL-2 day 21 IL-2 patient ) 6 . At relapse , applicable . The presence minimal residual disease bone marrow assess use multidimensional flow cytometry PCR . PROJECTED ACCRUAL : A total 400 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myeloid leukemia ( AML ) myelodysplastic syndrome enrol CCG 2961 AML treatment protocol Must one follow cytogenetic abnormality ( 8 ; 21 ) inv ( 16 ) abnormality 11q23 OR All patient enrol interleukin2 therapy standard care enrol time randomization PATIENT CHARACTERISTICS : Age : Children Performance status : Specified CCG 2961 AML treatment protocol Life expectancy : Specified CCG 2961 AML treatment protocol Hematopoietic : Specified CCG 2961 AML treatment protocol Hepatic : Specified CCG 2961 AML treatment protocol Renal : Specified CCG 2961 AML treatment protocol PRIOR CONCURRENT THERAPY : Specified CCG 2961 AML treatment protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>